Literature DB >> 11147985

Relation between prepublication release of clinical trial results and the practice of carotid endarterectomy.

C P Gross1, C A Steiner, E B Bass, N R Powe.   

Abstract

CONTEXT: Little is known about how clinical practice is affected by disseminating results of clinical trials prior to publication in peer-reviewed journals.
OBJECTIVE: To determine whether prepublication release of carotid endarterectomy (CEA) trial results via National Institutes of Health Clinical Alerts was associated with prompt changes in patient care that were consistent with the new medical evidence. DESIGN, SETTING, AND PATIENTS: Longitudinal data series analysis using acute care hospital discharge data from the Healthcare Cost and Utilization Project for patients who had CEA performed in acute care hospitals in 7 states (New York, California, Pennsylvania, Florida, Colorado, Illinois, and Wisconsin). The trials were the North American Symptomatic Carotid Endarterectomy Trial (NASCET clinical alert released February 1991) and the Asymptomatic Carotid Atherosclerosis Study (ACAS clinical alert released September 1994). MAIN OUTCOME MEASURE: Carotid endarterectomy rate during each month from 1989 (2 years before the NASCET clinical alert) to 1996 (2 years after the ACAS clinical alert), adjusted for age and sex. Because both trials were limited to patients 80 years or younger in hospitals with low mortality, we also stratified CEA rates by patient age and hospital mortality rate.
RESULTS: From 1989 through 1996, 272849 CEAs were performed in the acute care hospitals in these 7 states, with the annual number increasing from 22300 to 51 495. Afterthe NASCET clinical alert, the adjusted CEA rate increased 3.4% per month (95% confidence interval [CI], 1.6%-5.3%) during the following 6 months and then increased 0.5% per month (95% CI, 0.2%-0.8%; P<.04) after journal publication of the NASCET study. After the ACAS clinical alert, the CEA rate increased 7.3 % per month (95% CI, 6.0%-8.5%) during the following 7 months and then decreased by 0.44% per month (95% CI, -0.86% to -0.0002%; P<.04) after journal publication of the ACAS study. After the ACAS clinical alert, the CEA rate increased more in patients aged 80 years or older than in younger patients; whereas, after journal publication of ACAS, the CEA rate decreased more rapidly in the older population. The overall proportion of CEAs performed in low-mortality hospitals did not change substantially after release of the clinical alerts or after journal publication.
CONCLUSION: In this study, prepublication dissemination of CEA trial results with clinical alerts was associated with prompt and substantial changes in medical practice, but the observed changes suggest that the results were extrapolated to patients and settings not directly supported by the trials.

Entities:  

Mesh:

Year:  2000        PMID: 11147985     DOI: 10.1001/jama.284.22.2886

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  17 in total

1.  Performance of claims-based algorithms for identifying heart failure and cardiomyopathy among patients diagnosed with breast cancer.

Authors:  Larry A Allen; Marianne Ulcickas Yood; Edward H Wagner; Erin J Aiello Bowles; Roy Pardee; Robert Wellman; Laurel Habel; Larissa Nekhlyudov; Robert L Davis; Adedayo A Onitilo; David J Magid
Journal:  Med Care       Date:  2014-05       Impact factor: 2.983

2.  Impact of high dose statin trials on hospital prescribers.

Authors:  Thomas I Barron; Kathleen Bennett; John Feely
Journal:  Eur J Clin Pharmacol       Date:  2006-11-18       Impact factor: 2.953

3.  Be careful what you believe.

Authors:  Chris Hoag
Journal:  Can Urol Assoc J       Date:  2013 May-Jun       Impact factor: 1.862

4.  Association Between the Publication of Clinical Evidence and the Use of Bariatric Surgery.

Authors:  David D Kim; David E Arterburn; Sean D Sullivan; Anirban Basu
Journal:  Obes Surg       Date:  2018-05       Impact factor: 4.129

5.  The impact of clinical trials on the use of hormone replacement therapy. A population-based study.

Authors:  Nancy Kim; Cary Gross; Jeptha Curtis; Glen Stettin; Stephen Wogen; Nami Choe; Harlan M Krumholz
Journal:  J Gen Intern Med       Date:  2005-11       Impact factor: 5.128

6.  Minorities Are Underrepresented in Clinical Trials of Pharmaceutical Agents for Cystic Fibrosis.

Authors:  Meghan E McGarry; Susanna A McColley
Journal:  Ann Am Thorac Soc       Date:  2016-10

7.  Financial Burden of Cancer Clinical Trial Participation and the Impact of a Cancer Care Equity Program.

Authors:  Ryan D Nipp; Hang Lee; Elizabeth Powell; Nicole E Birrer; Emily Poles; Daniel Finkelstein; Karen Winkfield; Sanja Percac-Lima; Bruce Chabner; Beverly Moy
Journal:  Oncologist       Date:  2016-03-14

8.  [Study protocol of the VISEP study. Response of the SepNet study group].

Authors:  K Reinhart; F M Brunkhorst; C Engel; F Bloos; A Meier-Hellmann; M Ragaller; N Weiler; O Moerer; M Gruendling; M Oppert; S Grond; D Olthoff; U Jaschinski; S John; R Rossaint; T Welte; M Schaefer; P Kern; E Kuhnt; M Kiehntopf; T Deufel; C Hartog; H Gerlach; F Stüber; H-D Volk; M Quintel; M Loeffler
Journal:  Anaesthesist       Date:  2008-07       Impact factor: 1.041

9.  A most stubborn bias: no adjustment method fully resolves confounding by indication in observational studies.

Authors:  Jaclyn L F Bosco; Rebecca A Silliman; Soe Soe Thwin; Ann M Geiger; Diana S M Buist; Marianne N Prout; Marianne Ulcickas Yood; Reina Haque; Feifei Wei; Timothy L Lash
Journal:  J Clin Epidemiol       Date:  2009-05-19       Impact factor: 6.437

10.  Helping journalists get it right: a physicians's guide to improving health care reporting.

Authors:  Karen Stamm; John W Williams; Polly Hitchcock Noël; Rita Rubin
Journal:  J Gen Intern Med       Date:  2003-02       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.